This study concerns contralateral white noise suppression of transient evoked otoacoustic emissions (TEOAEs) in children with auditory processing disorder (APD). Fifty-one children between 7 and 11 years were assigned to 1 of 3 experimental groups: those without auditory complaints (n = 15), those with APD who scored high on a standardized test (n = 20) and those with APD who scored lower on the same test (n = 16). For all groups TEOAE suppression was determined in both linear and nonlinear acquisition mode. The results provide evidence that abnormal TEOAE suppression was significantly more common in the APD groups than in the control group. Contralateral suppression of TEOAE is an additional tool for assessing the efferent pathway in children with APD.

1.
Abdala C, Ma E, Sininger YS: Maturation of medial efferent system function in humans. J Acoust Soc Am 1999;105:2392–2402.
2.
Bamiou DE, Musiek FE, Luxon LM: Aetiology and clinical presentations of auditory processing disorders – a review. Arch Dis Child 2001;85:361–365.
3.
Berlin CI, Hood LJ, Wen H, Szabo P, Cecola RP, Rigby P, Jackson DF: Contralateral suppression of non-linear click-evoked otoacoustic emissions. Hear Res 1993;71:1–11.
4.
Chermak GD: Deciphering auditory processing disorders in children. Otolaryngol Clin North Am 2002;35:733–749.
5.
Chermak GD, Musiek FE: Central Auditory Processing Disorders. New Perspectives. San Diego, Singular Publishing Group, 1997.
6.
Collet L, Kemp DT, Veuillet E, Duclaux R, Moulin A, Morgon A: Effects of contralateral auditory stimuli on active cochlear micro-mechanical properties in human subjects. Hear Res 1990;43:251–262.
7.
De Ceulaer G, Yperman M, Daemers K, Van Driessche K, Somers T, Offeciers E, Govaerts PJ: Contralateral suppression of transient evoked otoacoustic emissions: normative data for a clinical test set-up. Otol Neurotol 2001;22:350–355.
8.
Durante AS, Carvallo RM: Contralateral suppression of otoacoustic emissions in neonates. Int J Audiol 2002;41:211–215.
9.
Giraud AL, Garnier S, Micheyl C, Lina G, Chays A, Chéry-Croze S: Auditory efferents involved in speech-in-noise intelligibility. Neuroreport 1997;8:1779–1783.
10.
Hood LJ, Berlin CI, Hurley A, Ceccola RP, Bell B: Contralateral suppression of transient evoked otoacoustic emissions in humans: intensity effects. Hear Res 1996;101:113–118.
11.
Jerger J, Musiek FE: Report of the Consensus Conference on the Diagnosis of Auditory Processing Disorders in School-Aged Children. J Am Acad Audiol 2000;11:467–474.
12.
Kakigi A, Hirakawa H, Mount RJ, Harrison RV: The effects of crossed olivocochlear bundle section on transient evoked otoacoustic emissions. Hear Res 1997;110:34–38.
13.
Kemp DT, Ryan S, Bray P: A guide to effective use of otoacoustic emissions. Ear Hear 1990;11:93–105.
14.
Kumar UA, Vanaja CS: Functioning of olivocochlear bundle and speech perception in noise. Ear Hear 2004;25:142–146.
15.
May BJ, Budelis J, Niparko JK: Behavioral studies of the olivocochlear efferent system: learning to listen in noise. Arch Otolaryngol Head Neck Surg 2004;130:660–664.
16.
Micheyl C, Collet L: Involvement of the olivocochlear bundle in the detection of tones in noise. J Acoust Soc Am 1996;99:1604–1610.
17.
Moleti A, Sisto R, Lucertini M: Linear and nonlinear transient evoked otoacoustic emissions in humans exposed to noise. Hear Res 2002;174:290–925.
18.
Morlet T, Goforth L, Hood LJ, Ferber C, Duclaux R, Berlin CI: Development of human cochlear active mechanism asymmetry: involvement of the medial olivocochlear system? Hear Res 1999;134:153–162.
19.
Muchnik C, Ari-Even Roth D, Othman-Jebara R, Putter-Katz H, Shabtai EL, Hildesheimer M: Reduced medial olivocochlear bundle system function in children with auditory processing disorders. Audiol Neurootol 2004;9:107–117.
20.
Musiek FE: Central auditory tests. Scand Audiol 1999;28(suppl 51):33–46.
21.
Parthasarathy TK: Aging and contralateral suppression effects on transient evoked otoacoustic emissions. J Am Acad Audiol 2001;12:80–85.
22.
Probst R, Harris FP: Otoacoustic emissions. Adv Otorhinolaryngol 1997;53:182–204.
23.
Rajan R: Electrical stimulation of the inferior colliculus at low rates protects the cochlea from auditory desensitization. Brain Res 1990;506:192–204.
24.
Ryan S, Kemp DT: The influence of evoking stimulus level on the neural suppression of transient evoked otoacoustic emissions. Hear Res 1996;94:140–147.
25.
Sahley TL, Nodar RH, Musiek FE: Efferent Auditory System. Structure and Function. San Diego, Singular Publishing Group, 1997.
26.
Salvi RJ, Lockwood AH, Frisina RD, Coad ML, Wack DS, Frisina DR: PET imaging of the normal human auditory system: responses to speech in quiet and in background noise. Hear Res 2002;170:96–106.
27.
Scharf B, Magnan J, Collet L, Ulmer E, Chays A: On the role of the olivocochlear bundle in hearing: a case study. Hear Res 1994;75:11–26.
28.
Schochat E: (Avaliação do processamento auditivo: revisão de literatura). RBM ORL 1998;5:24–31.
29.
Veuillet E, Collet L, Duclaux R: Effect of contralateral acoustic stimulation on active cochlear micromechanical properties in human subjects: dependence on stimulus variables. J Neurophysiol 1991;65:724–734.
30.
Warr WB, Guinan JJ: Efferent innervation of the organ of Corti: two separate systems. Brain Res 1979;173:152–155.
31.
Warren EH, Liberman MC: Effects of contralateral sound on auditory nerve responses: contributions of cochlear efferents. Hear Res 1989;37:89–104.
32.
Williams EA, Brooks GB, Prasher DK: Effects of olivocochlear bundle section on otoacoustic emissions in humans: efferent effects in comparison with control subjects. Acta Otolaryngol (Stockh) 1994;114:121–129.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.